Presentation on theme: "Clinical bioequivalence. Specific example n A manufacturer wishes to change its approved production method for standardized fedweed pollen extract n CBER."— Presentation transcript:
Specific example n A manufacturer wishes to change its approved production method for standardized fedweed pollen extract n CBER acknowledges that existing in vitro potency tests will be applicable to the new preparation. However, CBER requests that the manufacturer demonstrate compositional similarity by parallel line bioassay
“At least 4 subjects are required per assay. One or more test extracts are to be compared against a reference in each subject. For evaluating compositional differences, subjects…selectively sensitive to specific allergens in the crude mix should be selected…[I]n order to enhance detection of compositional differences, subjects can be selected who differ widely (10-10,000 fold) in their allergen skin test sensitivity…to the test of reference extracts.”
Manufacturer proposal n Based on the 1993 protocol, the manufacturer proposes to enlist 4 to 6 study subjects of varying levels of sensitivity to fedweed pollen n If the slopes of the two preparations are not significantly different in these study subjects, the manufacturer will conclude that the two preparations are compositionally similar
Initial assumptions n Mean slope: 10 n Acceptable difference: 10% = 1 n SD slope: 1 n = 0.05 = 0.2 = 0.2
Conclusions n The failure to demonstrate a difference is not sufficient to demonstrate equivalence Given that, for the parallel line bioassay, , the number of study subjects required to demonstrate equivalence will usually exceed 4-6 Given that, for the parallel line bioassay, , the number of study subjects required to demonstrate equivalence will usually exceed 4-6
Advisory Committee discussion CBER requests that the Committee discuss CBER’s current approach to clinical bioequivalence studies as it applies to allergen extract studies.
Your consent to our cookies if you continue to use this website.